3,4-Dihydro-6-methyl-2H-1-benzopyran | 3722-74-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 3,4-Dihydro-6-methyl-2H-1-benzopyran
• 英文别名: 6-methylchroman；6-Methyl-chroman；6-methyl-3,4-dihydro-2H-1-benzopyran；6-methyl-3,4-dihydro-2H-chromene
• CAS: 3722-74-5
• 化学式: C₁₀H₁₂O
• mdl: MFCD14705883
• 分子量: 148.205
• InChiKey: IBUHLIDJSRXQFP-UHFFFAOYSA-N

物化性质

• 沸点：
  234°C (estimate)
• 密度：
  1.0374

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3,4-Dihydro-6-methyl-2H-1-benzopyran 在 硼烷 、 四氯化钛 、 potassium hydrogencarbonate 作用下， 以 四氢呋喃 、 甲醇 、 硝基甲烷 为溶剂， 反应 20.5h， 生成
  参考文献：
  名称：

  Structure-Based Design of an Inhibitor of the Zinc Peptidase Thermolysin

  摘要：

  The full cycle of design, synthesis, and enzymatic and crystallographic evaluation of a structure-based inhibitor of thermolysin is described. Using the structure of the complex of thermolysin with Cbz-Gly(P)-Leu-Leu (K-i = 9 nM; ''Gly(P)'' = NHCH2PO2-) as the starting point, we designed the macrocyclic phosphonamidate (S,S)-1 as a conformationally constrained derivative. The chroman linking unit was designed to rigidify the peptide analog while avoiding unfavorable steric interactions with the enzyme. (S,S)-1 was synthesized by a route that provided all of the stereoisomers in pure form; the acyclic control compounds 2 and 3 were also prepared. The binding affinity of (S,S)-1 (K-i = 4 nM) is enhanced by 2.3 kcal/mol in comparison to 3 (K-i = 190 nM); the other diastereomers of 1 are considerably less potent (K-i greater than or equal to 500 nM). Crystallographic analysis of the complexes between thermolysin and (S,S)-1 and (S)-2 demonstrated that the anticipated mode of binding of (S,S)-1 was fundamentally correct, while revealing some discrepancies with the original model. The structural studies also showed that the chroman moiety in the acyclic analog (S)-2 binds in a different orientation than in the macrocycle, an observation that is important for interpreting the differences in affinity between the macrocyclic inhibitor and the control compounds.

  DOI：

  10.1021/ja00087a010
• 作为产物：
  描述：

  6-甲基香豆素 在 copper oxide-chromium oxide 、 三溴化磷 、 苯 作用下， 250.0 ℃ 、19.61 MPa 条件下， 生成 3,4-Dihydro-6-methyl-2H-1-benzopyran
  参考文献：
  名称：

  The Hydrogenation of Some Substituted Coumarins¹

  摘要：

  DOI：

  10.1021/ja01868a050

文献信息

• [EN] HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES POUR LE TRAITEMENT D'ÉTATS LIÉS AU STRESS
  申请人：OTSUKA PHARMA CO LTD

  公开号：WO2010137738A1

  公开（公告）日：2010-12-02

  The present invention provides a novel heterocyclic compound. A heterocyclic compound represented by general formula (1) wherein, R1 and R2, each independently represent hydrogen; a phenyl lower alkyl group that may have a substituent(s) selected from the group consisting of a lower alkyl group and the like on a benzene ring and/or a lower alkyl group; or a cyclo C3-C8 alkyl lower alkyl group; or the like; R3 represents a lower alkynyl group or the like; R4 represents a phenyl group that may have a substituent(s) selected from the group consisting of a 1,3,4-oxadiazolyl group that may have e.g., halogen or a heterocyclic group selected from pyridyl group and the like; the heterocyclic group may have at least one substituent(s) selected from a lower alkoxy group and the like or a salt thereof.

  本发明提供了一种新颖的杂环化合物。一种由通式（1）表示的杂环化合物，其中，R1和R2分别独立表示氢；苯基较低烷基基团，可能在苯环和/或较低烷基基团上具有从较低烷基基团等组成的取代基；或环C3-C8烷基较低烷基基团；或类似物；R3表示较低炔基基团或类似物；R4表示可能具有从1,3,4-噁二唑基团（例如，卤素）或从吡啶基团等组成的取代基的苯基团；所述杂环基可能具有至少一个从较低烷氧基等选择的取代基或其盐。
• Triazolone derivatives
  申请人：Clark Richard

  公开号：US20080015199A1

  公开（公告）日：2008-01-17

  A Compound represented by the following general formula (1), salts thereof or hydrates of the foregoing is a novel compound useful for treatment and/or prevention of diseases associated with thrombus formation, and which is safer with suitable physicochemical stability. [wherein R 1a , R 1b , R 1c and R 1d each independently represent hydrogen, etc.; R 2 represents optionally substituted phenyl, etc.; R 3 represents optionally substituted C6-10 aryl, etc.; and Z 1 and Z 2 each independently represent hydrogen]

  以下一般式（1）表示的化合物，其盐或上述化合物的水合物是一种新型化合物，可用于治疗和/或预防与血栓形成相关的疾病，并且具有适当的物理化学稳定性，更安全。 [其中R1a，R1b，R1c和R1d分别独立表示氢等；R2表示可选择取代的苯基等；R3表示可选择取代的C6-10芳基等；Z1和Z2分别独立表示氢]
• HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER
  申请人：Asana Biosciences, LLC

  公开号：US20160362407A1

  公开（公告）日：2016-12-15

  The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful for inhibiting ERK1/2. By administering to a patient in need a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, Z, J, M, and R 1 to R 8 are defined herein, these compounds are effective in treating conditions associated with dysregulation of the RAS/RAF/MEK/ERK pathway. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.

  本申请提供了新颖的杂环化合物及其药用可接受的盐。还提供了制备这些化合物的方法。这些化合物对抑制ERK1/2有用。通过向需要治疗的患者施用式(I)的一个或多个化合物的治疗有效量，其中X、Y、Z、J、M和R1至R8在此处定义，这些化合物在治疗与RAS/RAF/MEK/ERK通路失调相关的疾病方面是有效的。可以使用这些化合物治疗各种疾病，包括以异常细胞增殖为特征的疾病。在一个实施例中，该疾病是癌症。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• NOVEL COMPOUNDS
  申请人：RUDOLF Klaus

  公开号：US20130150355A1

  公开（公告）日：2013-06-13

  This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R 1 , R 2 , R 3 , R 3a have meanings given in the description.

  这项发明涉及到式I的化合物，它们作为mGlu5受体活性的正向变构调节剂的用途，含有这些化合物的药物组合物，以及将其用作治疗和/或预防与谷氨酸功能障碍相关的神经和精神障碍的药剂，如精神分裂症或认知功能下降，如痴呆症或认知障碍。A、B、Ar、R1、R2、R3、R3a在描述中有给定的含义。